Anthony S. Gibney - 02 Jun 2025 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Financial and Business Officer.
Signature
/s/ Conor Kilroy, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
02 Jun 2025
Net transactions value
$0
Form type
4
Filing time
04 Jun 2025, 16:05:33 UTC
Previous filing
20 May 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gibney Anthony S Chief Financial and Business Officer. C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON /s/ Conor Kilroy, as Attorney-in-Fact 04 Jun 2025 0001750132

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +150,000 +263% $0.000000 206,933 02 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award $0 +250,000 $0.000000 250,000 02 Jun 2025 Common Stock 250,000 $6.16 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on June 15, 2026, subject to the Reporting Person's continued service as of each such vesting date.
F2 The shares underlying this option vest as follows: 25% of the shares vest on May 13, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

Chief Financial and Business Officer.